Shots:

• The P-III NEPTUNE study involves assessing of Imfinzi + tremelimumab vs SOC platinum-based CT as a 1L treatment in patients with Stage IV metastatic NSCLC + high tumor mutational burden (TMB) across 29 countries including the US- Europe- South and Central America- the Middle East and Asia.
• The P-III NEPTUNE study results demonstrated that it did not meet 1EPs i.e- OS in patients with high blood TMB defined as ≥ 20 mut/Mb while its safety and tolerability profile is consistent with previous studies
• Imfinzi is a mAb targeting PD-L1- blocking its interaction with PD-1 and CD80- currently being evaluated in P-III PEARL study as monothx. and in combination with CT with/out tremelimumab in the P-III POSEIDON for Stage IV NSCLC

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca